OBJECTIVES : The mortality of acute myocardial infarction（AMI）and the prevalence of dyslipidemia in China increases rapidly. Dyslipidemia is an important risk factor for AMI and contributes serious disease burden. Dyslipidemia patients who have experienced AMI have higher risks of cardiovascular events and heavier burden of disease. This study reported key findings on the cost of Chinese patients with AMI combining dyslipidemia.

METHODS : Patients hospitalized in 2016 due to AMI combining dyslipidemia from six hospitals in different geographic areas of China were enrolled. Direct medical cost was derived from electronic medical records; direct non-medical cost and indirect cost were collected by a face-to-face questionnaire survey. The analysis was based on descriptive statistics.

RESULTS : Data of 683 patients were analyzed excluding 129 deaths. The mean age was 58.8 (SD: 13) and patients aged 51 to 70 were the majority (55.20%). Males (80.53%) were significantly more than females. Medium direct medical cost of inpatient and outpatient per visit were 42,600 RMB (QL: 14,570; QU: 58,822) and 503 RMB (QL: 292; QU: 806), respectively; accordingly medium direct non-medical cost per visit were 913 RMB (QL: 513; QU: 1513) and 20 RMB (QL: 0; QU: 80), respectively. The medium inpatient and outpatient indirect cost was 740 RMB (QL: 0; QU: 1,600) and 0 RMB (QL: 0; QU: 50), respectively. The numbers of inpatient and outpatient visits per patient were 1 (QL: 1; QU: 2) and 17 (QL: 7; QU: 34), respectively.

CONCLUSIONS : This study used real world data and analyzed the costs of AMI combining dyslipidemia in China comprehensively. The hospitalization cost was high for our study population irrespective of the type of cost. Providing dyslipidemia prevention and control intervention as well as effective disease management would likely make contribution to reducing cost, especially for middle-aged and elderly patients with dyslipidemia.